U.S. Markets closed
  • S&P 500

    4,704.54
    +15.87 (+0.34%)
     
  • Dow 30

    35,870.95
    -60.10 (-0.17%)
     
  • Nasdaq

    15,993.71
    +72.14 (+0.45%)
     
  • Russell 2000

    2,363.59
    -13.42 (-0.56%)
     
  • Gold

    1,861.20
    -0.20 (-0.01%)
     
  • Silver

    24.88
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1369
    -0.0006 (-0.0568%)
     
  • 10-Yr Bond

    1.5890
    -0.0150 (-0.94%)
     
  • Vix

    17.59
    +0.48 (+2.81%)
     
  • GBP/USD

    1.3497
    -0.0003 (-0.0216%)
     
  • USD/JPY

    114.3040
    +0.0520 (+0.0455%)
     
  • BTC-USD

    54,350.48
    -3,275.72 (-5.68%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     
  • FTSE 100

    7,255.96
    -35.24 (-0.48%)
     
  • Nikkei 225

    29,683.09
    +84.43 (+0.29%)
     

Kindred Biosciences Submits Efficacy Data For KIND-030 As Prophylactic Option In US

·1 min read
  • Kindred Biosciences Inc (NASDAQ: KIN) has submitted efficacy data to support the prophylactic indication for KIND-030 to the United States Department of Agriculture Center for Veterinary Biologics for review.

  • KIND-030 is a monoclonal antibody targeting canine parvovirus infection.

  • In September last year, Kindred Bio reported positive results from its pivotal efficacy study that showed a 60% mortality rate in the control dogs, compared to 0% in the KIND-030 treated dogs.

  • KIND-030 is being pursued for two indications in dogs - prophylactic therapy to prevent clinical signs of canine parvovirus infection, and treatment of established parvovirus infection.

  • The completion of the upcoming pivotal efficacy study for the treatment indication for KIND-030 is extended into the second quarter of 2021.

  • In December, Elanco Animal Health Inc (NYSE: ELANentered into an agreement with Kindred Biosciences to acquire exclusive global rights to KIND-030.

  • Price Action: KIN is down 0.4% at $4.71 in market trading hours on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.